nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP3A5—Teniposide—lymphatic system cancer	0.125	0.201	CbGbCtD
Nefazodone—CYP3A7—Vincristine—lymphatic system cancer	0.0801	0.129	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0801	0.129	CbGbCtD
Nefazodone—CYP3A5—Vincristine—lymphatic system cancer	0.0601	0.0969	CbGbCtD
Nefazodone—ABCB1—Mitoxantrone—lymphatic system cancer	0.0568	0.0916	CbGbCtD
Nefazodone—CYP3A4—Cytarabine—lymphatic system cancer	0.0494	0.0797	CbGbCtD
Nefazodone—CYP3A4—Teniposide—lymphatic system cancer	0.0487	0.0785	CbGbCtD
Nefazodone—ABCB1—Vincristine—lymphatic system cancer	0.0391	0.063	CbGbCtD
Nefazodone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.034	0.0549	CbGbCtD
Nefazodone—ABCB1—Methotrexate—lymphatic system cancer	0.0237	0.0382	CbGbCtD
Nefazodone—CYP3A4—Vincristine—lymphatic system cancer	0.0234	0.0378	CbGbCtD
Nefazodone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000729	0.00192	CcSEcCtD
Nefazodone—Asthenia—Teniposide—lymphatic system cancer	0.000722	0.0019	CcSEcCtD
Nefazodone—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000718	0.00189	CcSEcCtD
Nefazodone—Malaise—Bleomycin—lymphatic system cancer	0.000716	0.00189	CcSEcCtD
Nefazodone—Pruritus—Teniposide—lymphatic system cancer	0.000712	0.00187	CcSEcCtD
Nefazodone—Leukopenia—Bleomycin—lymphatic system cancer	0.000711	0.00187	CcSEcCtD
Nefazodone—Cystitis—Methotrexate—lymphatic system cancer	0.00071	0.00187	CcSEcCtD
Nefazodone—Alopecia—Carmustine—lymphatic system cancer	0.000704	0.00185	CcSEcCtD
Nefazodone—Body temperature increased—Fludarabine—lymphatic system cancer	0.000699	0.00184	CcSEcCtD
Nefazodone—Vaginal infection—Methotrexate—lymphatic system cancer	0.000694	0.00183	CcSEcCtD
Nefazodone—Cough—Bleomycin—lymphatic system cancer	0.000693	0.00183	CcSEcCtD
Nefazodone—Diarrhoea—Teniposide—lymphatic system cancer	0.000688	0.00181	CcSEcCtD
Nefazodone—Chest pain—Bleomycin—lymphatic system cancer	0.000676	0.00178	CcSEcCtD
Nefazodone—Myalgia—Bleomycin—lymphatic system cancer	0.000676	0.00178	CcSEcCtD
Nefazodone—Alopecia—Vincristine—lymphatic system cancer	0.000672	0.00177	CcSEcCtD
Nefazodone—Back pain—Carmustine—lymphatic system cancer	0.000671	0.00177	CcSEcCtD
Nefazodone—Discomfort—Bleomycin—lymphatic system cancer	0.000668	0.00176	CcSEcCtD
Nefazodone—Chills—Mitoxantrone—lymphatic system cancer	0.000665	0.00175	CcSEcCtD
Nefazodone—Ecchymosis—Methotrexate—lymphatic system cancer	0.000664	0.00175	CcSEcCtD
Nefazodone—Bladder pain—Methotrexate—lymphatic system cancer	0.000664	0.00175	CcSEcCtD
Nefazodone—Urine output increased—Methotrexate—lymphatic system cancer	0.000664	0.00175	CcSEcCtD
Nefazodone—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000664	0.00175	CcSEcCtD
Nefazodone—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000657	0.00173	CcSEcCtD
Nefazodone—Alopecia—Mitoxantrone—lymphatic system cancer	0.000654	0.00172	CcSEcCtD
Nefazodone—Confusional state—Bleomycin—lymphatic system cancer	0.000654	0.00172	CcSEcCtD
Nefazodone—Vision blurred—Carmustine—lymphatic system cancer	0.000654	0.00172	CcSEcCtD
Nefazodone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000652	0.00172	CcSEcCtD
Nefazodone—Tremor—Carmustine—lymphatic system cancer	0.00065	0.00171	CcSEcCtD
Nefazodone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000648	0.00171	CcSEcCtD
Nefazodone—Oedema—Bleomycin—lymphatic system cancer	0.000648	0.00171	CcSEcCtD
Nefazodone—Infection—Bleomycin—lymphatic system cancer	0.000644	0.0017	CcSEcCtD
Nefazodone—Anaemia—Carmustine—lymphatic system cancer	0.000641	0.00169	CcSEcCtD
Nefazodone—Back pain—Vincristine—lymphatic system cancer	0.00064	0.00169	CcSEcCtD
Nefazodone—Vomiting—Teniposide—lymphatic system cancer	0.00064	0.00168	CcSEcCtD
Nefazodone—Agitation—Carmustine—lymphatic system cancer	0.000637	0.00168	CcSEcCtD
Nefazodone—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000635	0.00167	CcSEcCtD
Nefazodone—Asthenia—Fludarabine—lymphatic system cancer	0.000634	0.00167	CcSEcCtD
Nefazodone—Rash—Teniposide—lymphatic system cancer	0.000634	0.00167	CcSEcCtD
Nefazodone—Dermatitis—Teniposide—lymphatic system cancer	0.000634	0.00167	CcSEcCtD
Nefazodone—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000631	0.00166	CcSEcCtD
Nefazodone—Headache—Teniposide—lymphatic system cancer	0.00063	0.00166	CcSEcCtD
Nefazodone—Pruritus—Fludarabine—lymphatic system cancer	0.000626	0.00165	CcSEcCtD
Nefazodone—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000625	0.00165	CcSEcCtD
Nefazodone—Back pain—Mitoxantrone—lymphatic system cancer	0.000624	0.00164	CcSEcCtD
Nefazodone—Leukopenia—Carmustine—lymphatic system cancer	0.000621	0.00163	CcSEcCtD
Nefazodone—Anorexia—Bleomycin—lymphatic system cancer	0.000618	0.00163	CcSEcCtD
Nefazodone—Anaemia—Vincristine—lymphatic system cancer	0.000612	0.00161	CcSEcCtD
Nefazodone—Agitation—Vincristine—lymphatic system cancer	0.000608	0.0016	CcSEcCtD
Nefazodone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000608	0.0016	CcSEcCtD
Nefazodone—Polyuria—Methotrexate—lymphatic system cancer	0.000607	0.0016	CcSEcCtD
Nefazodone—Hypotension—Bleomycin—lymphatic system cancer	0.000606	0.0016	CcSEcCtD
Nefazodone—Diarrhoea—Fludarabine—lymphatic system cancer	0.000605	0.00159	CcSEcCtD
Nefazodone—Convulsion—Carmustine—lymphatic system cancer	0.000601	0.00158	CcSEcCtD
Nefazodone—Hypertension—Carmustine—lymphatic system cancer	0.000599	0.00158	CcSEcCtD
Nefazodone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000598	0.00157	CcSEcCtD
Nefazodone—Nausea—Teniposide—lymphatic system cancer	0.000598	0.00157	CcSEcCtD
Nefazodone—Anaemia—Mitoxantrone—lymphatic system cancer	0.000596	0.00157	CcSEcCtD
Nefazodone—Vertigo—Vincristine—lymphatic system cancer	0.000595	0.00157	CcSEcCtD
Nefazodone—Hepatic failure—Methotrexate—lymphatic system cancer	0.000594	0.00156	CcSEcCtD
Nefazodone—Leukopenia—Vincristine—lymphatic system cancer	0.000593	0.00156	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000591	0.00156	CcSEcCtD
Nefazodone—Chest pain—Carmustine—lymphatic system cancer	0.00059	0.00155	CcSEcCtD
Nefazodone—Myalgia—Carmustine—lymphatic system cancer	0.00059	0.00155	CcSEcCtD
Nefazodone—Anxiety—Carmustine—lymphatic system cancer	0.000588	0.00155	CcSEcCtD
Nefazodone—Paraesthesia—Bleomycin—lymphatic system cancer	0.000582	0.00153	CcSEcCtD
Nefazodone—Malaise—Mitoxantrone—lymphatic system cancer	0.000581	0.00153	CcSEcCtD
Nefazodone—Dyspnoea—Bleomycin—lymphatic system cancer	0.000578	0.00152	CcSEcCtD
Nefazodone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000577	0.00152	CcSEcCtD
Nefazodone—Convulsion—Vincristine—lymphatic system cancer	0.000574	0.00151	CcSEcCtD
Nefazodone—Hypertension—Vincristine—lymphatic system cancer	0.000572	0.0015	CcSEcCtD
Nefazodone—Confusional state—Carmustine—lymphatic system cancer	0.000571	0.0015	CcSEcCtD
Nefazodone—Oedema—Carmustine—lymphatic system cancer	0.000566	0.00149	CcSEcCtD
Nefazodone—Decreased appetite—Bleomycin—lymphatic system cancer	0.000564	0.00148	CcSEcCtD
Nefazodone—Myalgia—Vincristine—lymphatic system cancer	0.000564	0.00148	CcSEcCtD
Nefazodone—Visual disturbance—Methotrexate—lymphatic system cancer	0.000563	0.00148	CcSEcCtD
Nefazodone—Cough—Mitoxantrone—lymphatic system cancer	0.000563	0.00148	CcSEcCtD
Nefazodone—Infection—Carmustine—lymphatic system cancer	0.000562	0.00148	CcSEcCtD
Nefazodone—Vomiting—Fludarabine—lymphatic system cancer	0.000562	0.00148	CcSEcCtD
Nefazodone—Convulsion—Mitoxantrone—lymphatic system cancer	0.000559	0.00147	CcSEcCtD
Nefazodone—Rash—Fludarabine—lymphatic system cancer	0.000558	0.00147	CcSEcCtD
Nefazodone—Dermatitis—Fludarabine—lymphatic system cancer	0.000557	0.00147	CcSEcCtD
Nefazodone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000557	0.00147	CcSEcCtD
Nefazodone—Pain—Bleomycin—lymphatic system cancer	0.000554	0.00146	CcSEcCtD
Nefazodone—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000554	0.00146	CcSEcCtD
Nefazodone—Headache—Fludarabine—lymphatic system cancer	0.000554	0.00146	CcSEcCtD
Nefazodone—Tachycardia—Carmustine—lymphatic system cancer	0.000552	0.00145	CcSEcCtD
Nefazodone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000549	0.00145	CcSEcCtD
Nefazodone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000549	0.00145	CcSEcCtD
Nefazodone—Chest pain—Mitoxantrone—lymphatic system cancer	0.000549	0.00145	CcSEcCtD
Nefazodone—Anxiety—Mitoxantrone—lymphatic system cancer	0.000547	0.00144	CcSEcCtD
Nefazodone—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000544	0.00143	CcSEcCtD
Nefazodone—Discomfort—Mitoxantrone—lymphatic system cancer	0.000542	0.00143	CcSEcCtD
Nefazodone—Oedema—Vincristine—lymphatic system cancer	0.00054	0.00142	CcSEcCtD
Nefazodone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00054	0.00142	CcSEcCtD
Nefazodone—Anorexia—Carmustine—lymphatic system cancer	0.000539	0.00142	CcSEcCtD
Nefazodone—Infection—Vincristine—lymphatic system cancer	0.000537	0.00141	CcSEcCtD
Nefazodone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000534	0.00141	CcSEcCtD
Nefazodone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000533	0.0014	CcSEcCtD
Nefazodone—Confusional state—Mitoxantrone—lymphatic system cancer	0.000531	0.0014	CcSEcCtD
Nefazodone—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000529	0.00139	CcSEcCtD
Nefazodone—Hypotension—Carmustine—lymphatic system cancer	0.000529	0.00139	CcSEcCtD
Nefazodone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000526	0.00139	CcSEcCtD
Nefazodone—Oedema—Mitoxantrone—lymphatic system cancer	0.000526	0.00139	CcSEcCtD
Nefazodone—Nausea—Fludarabine—lymphatic system cancer	0.000525	0.00138	CcSEcCtD
Nefazodone—Infection—Mitoxantrone—lymphatic system cancer	0.000523	0.00138	CcSEcCtD
Nefazodone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000522	0.00138	CcSEcCtD
Nefazodone—Shock—Mitoxantrone—lymphatic system cancer	0.000518	0.00136	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000516	0.00136	CcSEcCtD
Nefazodone—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000515	0.00136	CcSEcCtD
Nefazodone—Urticaria—Bleomycin—lymphatic system cancer	0.000515	0.00136	CcSEcCtD
Nefazodone—Anorexia—Vincristine—lymphatic system cancer	0.000515	0.00136	CcSEcCtD
Nefazodone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000514	0.00135	CcSEcCtD
Nefazodone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000513	0.00135	CcSEcCtD
Nefazodone—Insomnia—Carmustine—lymphatic system cancer	0.000512	0.00135	CcSEcCtD
Nefazodone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000509	0.00134	CcSEcCtD
Nefazodone—Paraesthesia—Carmustine—lymphatic system cancer	0.000508	0.00134	CcSEcCtD
Nefazodone—Mood swings—Methotrexate—lymphatic system cancer	0.000505	0.00133	CcSEcCtD
Nefazodone—Hypotension—Vincristine—lymphatic system cancer	0.000505	0.00133	CcSEcCtD
Nefazodone—Dyspnoea—Carmustine—lymphatic system cancer	0.000505	0.00133	CcSEcCtD
Nefazodone—Somnolence—Carmustine—lymphatic system cancer	0.000503	0.00132	CcSEcCtD
Nefazodone—Anorexia—Mitoxantrone—lymphatic system cancer	0.000502	0.00132	CcSEcCtD
Nefazodone—Ataxia—Methotrexate—lymphatic system cancer	0.000502	0.00132	CcSEcCtD
Nefazodone—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000492	0.0013	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000492	0.0013	CcSEcCtD
Nefazodone—Decreased appetite—Carmustine—lymphatic system cancer	0.000492	0.0013	CcSEcCtD
Nefazodone—Hypotension—Mitoxantrone—lymphatic system cancer	0.000492	0.00129	CcSEcCtD
Nefazodone—Insomnia—Vincristine—lymphatic system cancer	0.000489	0.00129	CcSEcCtD
Nefazodone—Paraesthesia—Vincristine—lymphatic system cancer	0.000485	0.00128	CcSEcCtD
Nefazodone—Pain—Carmustine—lymphatic system cancer	0.000484	0.00127	CcSEcCtD
Nefazodone—Constipation—Carmustine—lymphatic system cancer	0.000484	0.00127	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000479	0.00126	CcSEcCtD
Nefazodone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000478	0.00126	CcSEcCtD
Nefazodone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000472	0.00124	CcSEcCtD
Nefazodone—Decreased appetite—Vincristine—lymphatic system cancer	0.00047	0.00124	CcSEcCtD
Nefazodone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000469	0.00124	CcSEcCtD
Nefazodone—Somnolence—Mitoxantrone—lymphatic system cancer	0.000468	0.00123	CcSEcCtD
Nefazodone—Feeling abnormal—Carmustine—lymphatic system cancer	0.000466	0.00123	CcSEcCtD
Nefazodone—Asthenia—Bleomycin—lymphatic system cancer	0.000465	0.00122	CcSEcCtD
Nefazodone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000463	0.00122	CcSEcCtD
Nefazodone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000463	0.00122	CcSEcCtD
Nefazodone—Constipation—Vincristine—lymphatic system cancer	0.000462	0.00122	CcSEcCtD
Nefazodone—Pain—Vincristine—lymphatic system cancer	0.000462	0.00122	CcSEcCtD
Nefazodone—Asthma—Methotrexate—lymphatic system cancer	0.000461	0.00121	CcSEcCtD
Nefazodone—Pruritus—Bleomycin—lymphatic system cancer	0.000459	0.00121	CcSEcCtD
Nefazodone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000457	0.0012	CcSEcCtD
Nefazodone—Pain—Mitoxantrone—lymphatic system cancer	0.00045	0.00118	CcSEcCtD
Nefazodone—Constipation—Mitoxantrone—lymphatic system cancer	0.00045	0.00118	CcSEcCtD
Nefazodone—Body temperature increased—Carmustine—lymphatic system cancer	0.000447	0.00118	CcSEcCtD
Nefazodone—Abdominal pain—Carmustine—lymphatic system cancer	0.000447	0.00118	CcSEcCtD
Nefazodone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000442	0.00116	CcSEcCtD
Nefazodone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000434	0.00114	CcSEcCtD
Nefazodone—Dysuria—Methotrexate—lymphatic system cancer	0.000431	0.00113	CcSEcCtD
Nefazodone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00043	0.00113	CcSEcCtD
Nefazodone—Abdominal pain—Vincristine—lymphatic system cancer	0.000427	0.00112	CcSEcCtD
Nefazodone—Body temperature increased—Vincristine—lymphatic system cancer	0.000427	0.00112	CcSEcCtD
Nefazodone—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000425	0.00112	CcSEcCtD
Nefazodone—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000421	0.00111	CcSEcCtD
Nefazodone—Urticaria—Mitoxantrone—lymphatic system cancer	0.000418	0.0011	CcSEcCtD
Nefazodone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000417	0.0011	CcSEcCtD
Nefazodone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000416	0.0011	CcSEcCtD
Nefazodone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000416	0.0011	CcSEcCtD
Nefazodone—Pneumonia—Methotrexate—lymphatic system cancer	0.000413	0.00109	CcSEcCtD
Nefazodone—Vomiting—Bleomycin—lymphatic system cancer	0.000412	0.00109	CcSEcCtD
Nefazodone—Rash—Bleomycin—lymphatic system cancer	0.000409	0.00108	CcSEcCtD
Nefazodone—Dermatitis—Bleomycin—lymphatic system cancer	0.000408	0.00108	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000408	0.00107	CcSEcCtD
Nefazodone—Asthenia—Carmustine—lymphatic system cancer	0.000406	0.00107	CcSEcCtD
Nefazodone—Stomatitis—Methotrexate—lymphatic system cancer	0.000401	0.00105	CcSEcCtD
Nefazodone—Conjunctivitis—Methotrexate—lymphatic system cancer	0.0004	0.00105	CcSEcCtD
Nefazodone—Hypersensitivity—Vincristine—lymphatic system cancer	0.000398	0.00105	CcSEcCtD
Nefazodone—Sweating—Methotrexate—lymphatic system cancer	0.000394	0.00104	CcSEcCtD
Nefazodone—Haematuria—Methotrexate—lymphatic system cancer	0.000392	0.00103	CcSEcCtD
Nefazodone—Epistaxis—Methotrexate—lymphatic system cancer	0.000388	0.00102	CcSEcCtD
Nefazodone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000388	0.00102	CcSEcCtD
Nefazodone—Asthenia—Vincristine—lymphatic system cancer	0.000388	0.00102	CcSEcCtD
Nefazodone—Diarrhoea—Carmustine—lymphatic system cancer	0.000387	0.00102	CcSEcCtD
Nefazodone—Nausea—Bleomycin—lymphatic system cancer	0.000385	0.00101	CcSEcCtD
Nefazodone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000378	0.000994	CcSEcCtD
Nefazodone—Dizziness—Carmustine—lymphatic system cancer	0.000374	0.000985	CcSEcCtD
Nefazodone—Haemoglobin—Methotrexate—lymphatic system cancer	0.000371	0.000976	CcSEcCtD
Nefazodone—Diarrhoea—Vincristine—lymphatic system cancer	0.00037	0.000973	CcSEcCtD
Nefazodone—Haemorrhage—Methotrexate—lymphatic system cancer	0.000369	0.000971	CcSEcCtD
Nefazodone—Hepatitis—Methotrexate—lymphatic system cancer	0.000369	0.000971	CcSEcCtD
Nefazodone—Pharyngitis—Methotrexate—lymphatic system cancer	0.000366	0.000964	CcSEcCtD
Nefazodone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00036	0.000948	CcSEcCtD
Nefazodone—Vomiting—Carmustine—lymphatic system cancer	0.00036	0.000947	CcSEcCtD
Nefazodone—Dizziness—Vincristine—lymphatic system cancer	0.000357	0.000941	CcSEcCtD
Nefazodone—Rash—Carmustine—lymphatic system cancer	0.000357	0.00094	CcSEcCtD
Nefazodone—Dermatitis—Carmustine—lymphatic system cancer	0.000357	0.000939	CcSEcCtD
Nefazodone—Visual impairment—Methotrexate—lymphatic system cancer	0.000356	0.000936	CcSEcCtD
Nefazodone—Headache—Carmustine—lymphatic system cancer	0.000355	0.000934	CcSEcCtD
Nefazodone—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000349	0.000919	CcSEcCtD
Nefazodone—Tinnitus—Methotrexate—lymphatic system cancer	0.000344	0.000906	CcSEcCtD
Nefazodone—Vomiting—Vincristine—lymphatic system cancer	0.000344	0.000904	CcSEcCtD
Nefazodone—Rash—Vincristine—lymphatic system cancer	0.000341	0.000897	CcSEcCtD
Nefazodone—Dermatitis—Vincristine—lymphatic system cancer	0.00034	0.000896	CcSEcCtD
Nefazodone—Headache—Vincristine—lymphatic system cancer	0.000338	0.000891	CcSEcCtD
Nefazodone—Nausea—Carmustine—lymphatic system cancer	0.000336	0.000885	CcSEcCtD
Nefazodone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000335	0.000881	CcSEcCtD
Nefazodone—Rash—Mitoxantrone—lymphatic system cancer	0.000332	0.000873	CcSEcCtD
Nefazodone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000331	0.000873	CcSEcCtD
Nefazodone—Chills—Methotrexate—lymphatic system cancer	0.000331	0.000872	CcSEcCtD
Nefazodone—Headache—Mitoxantrone—lymphatic system cancer	0.00033	0.000868	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—lymphatic system cancer	0.000326	0.000858	CcSEcCtD
Nefazodone—Nausea—Vincristine—lymphatic system cancer	0.000321	0.000845	CcSEcCtD
Nefazodone—Dysgeusia—Methotrexate—lymphatic system cancer	0.000315	0.000828	CcSEcCtD
Nefazodone—Nausea—Mitoxantrone—lymphatic system cancer	0.000313	0.000823	CcSEcCtD
Nefazodone—Back pain—Methotrexate—lymphatic system cancer	0.000311	0.000818	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—lymphatic system cancer	0.000303	0.000797	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000298	0.000785	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—lymphatic system cancer	0.000297	0.000782	CcSEcCtD
Nefazodone—Malaise—Methotrexate—lymphatic system cancer	0.00029	0.000763	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—lymphatic system cancer	0.000289	0.00076	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—lymphatic system cancer	0.000288	0.000757	CcSEcCtD
Nefazodone—Cough—Methotrexate—lymphatic system cancer	0.00028	0.000738	CcSEcCtD
Nefazodone—Convulsion—Methotrexate—lymphatic system cancer	0.000278	0.000733	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—lymphatic system cancer	0.000273	0.00072	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—lymphatic system cancer	0.000273	0.00072	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—lymphatic system cancer	0.000273	0.00072	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—lymphatic system cancer	0.00027	0.000711	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—lymphatic system cancer	0.000264	0.000696	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000262	0.00069	CcSEcCtD
Nefazodone—Infection—Methotrexate—lymphatic system cancer	0.00026	0.000686	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000257	0.000676	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000253	0.000667	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—lymphatic system cancer	0.00025	0.000658	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—lymphatic system cancer	0.000245	0.000645	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000239	0.000629	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—lymphatic system cancer	0.000237	0.000624	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000235	0.00062	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000234	0.000615	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—lymphatic system cancer	0.000233	0.000614	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000231	0.000608	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000228	0.0006	CcSEcCtD
Nefazodone—Pain—Methotrexate—lymphatic system cancer	0.000224	0.00059	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000216	0.000569	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000214	0.000564	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—lymphatic system cancer	0.000208	0.000548	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000207	0.000546	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000207	0.000546	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000193	0.000509	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—lymphatic system cancer	0.000188	0.000495	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—lymphatic system cancer	0.000185	0.000488	CcSEcCtD
Nefazodone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000179	0.000472	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—lymphatic system cancer	0.000173	0.000456	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—lymphatic system cancer	0.000167	0.000439	CcSEcCtD
Nefazodone—Rash—Methotrexate—lymphatic system cancer	0.000165	0.000435	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—lymphatic system cancer	0.000165	0.000435	CcSEcCtD
Nefazodone—Headache—Methotrexate—lymphatic system cancer	0.000164	0.000432	CcSEcCtD
Nefazodone—Nausea—Methotrexate—lymphatic system cancer	0.000156	0.00041	CcSEcCtD
